Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Market Cap	7.05M
Revenue (ttm)	n/a
Net Income (ttm)	-6.59M
Shares Out	16.79M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,311
Open	0.400
Previous Close	0.410
Day's Range	0.390 - 0.420
52-Week Range	0.350 - 2.750
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 23, 2024

About SHPH

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treat...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Aug 31, 2022
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: SHPH